Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
Checkpoint immunotherapies have helped many patients by enabling their immune cells to stay active against cancer. Checkpoint immunotherapies can sometimes reinvigorate “exhausted” cells, but not always. Dr. Abdel Hakeem wants to understand what controls this exhaustion, specifically at the epigenetic level (where genes are turned on/off). Using a viral model called LCMV, he’s exploring epigenetic patterns associated with exhaustion that might suggest other ways to prevent and reverse it. These strategies might also work well with current checkpoint therapies and help provide patients with even better outcomes.
University of Pennsylvania School of Medicine | All Cancers, Lung Cancer, Melanoma | 2016 | E. John Wherry, Ph.D.
*Los resultados de la inmunoterapia pueden variar de un paciente a otro.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Ning Jenny Jiang, a CRI Lloyd J. Old STAR at the University of Pennsylvania, is working to improve personalized T cell therapies for cancer patients
This November for Stomach Cancer Awareness Month, let’s look at the latest treatments, research insights, and we're working toward a future immune to stomach cancer.